???global.info.a_carregar???
My name is Ricardo Miguel dos Santos Rodrigues, graduated member number 3859 of the Biologists' Order, and SPEDM number 1048. I completed my Bachelor¿s degree in Biology, in the field of Molecular Biology and Genetics, in 2019, in the Faculty of Sciences of Lisbon (FCUL), where I also obtained a Master¿s degree in Molecular Biology and Genetics in 2022. Currently I am a PhD student in the doctoral program in Health Sciences of NOVA Medical School | Faculdade de Ciências Médicas da Universidade NOVA de Lisboa. I developed a Master¿s dissertation entitled, "Study of molecular and cellular mechanisms involved in anaplastic thyroid carcinoma aggressiveness and response to therapy", which was supervised by Dr. Branca Cavaco, Principal Investigator of the Molecular Endocrinology Group, and co-supervised by Dr. Tiago Nunes da Silva, Endocrinologist and Researcher, held at Unidade de Investigação em Patobiologia Molecular (UIPM), at Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG). Aggressive thyroid cancer, specially anaplastic thyroid cancer (ATC) is the rarest form of thyroid cancer, but it is also the most aggressive and fatal form. My Master´s project aimed to understand the molecular and cellular mechanisms involved in ATC aggressiveness, and response/resistance to therapy, since these mechanisms are still poorly clarified. Throughout the project, I acquired a considerable theoretical knowledge, and laboratorial skills in molecular and cellular Biology, and particularly in the Oncobiology field. I am developing specific aspects of the above mentioned research, in the same group and I am currently PhD student in Health Sciences in NOVA medical School, entitled "Targeted therapy in aggressive thyroid cancer - unravelling novel resistance mechanisms, predictive biomarkers and therapeutic targets" Besides this scientific passion for cancer research, I have played soccer since I was eight years old, which allowed me to improve companionship, team effort, team trust, and commitment, which, in my opinion, are also important characteristics in a researcher.
Read full resume ↓
Identification

Personal identification

Full name
Ricardo Miguel dos Santos Rodrigues
Date of birth
1997/04/24
Gender
Male

Citation names

  • Rodrigues, Ricardo

Author identifiers

Ciência ID
6E17-05C3-3060
ORCID iD
0000-0003-1928-4106

Email addresses

  • rmrodrigues@ipolisboa.min-saude.pt (Professional)
  • ricarodrigues97@gmail.com (Personal)

Telephones

Mobile phone
  • 934683915 (Personal)

Websites

  • linkedin.com/in/ricardo-rodrigues-5639141a1 (Professional)

Knowledge fields

  • Natural sciences - Biological Sciences - Biology
  • Natural sciences - Biological Sciences - Molecular Biology
  • Natural sciences - Biological Sciences - Cell Biology

Languages

Language Speaking Reading Writing Listening Peer-review
Portuguese (Mother tongue)
English
Education
Degree Classification
2022/09/12 - 2026/09/30
Ongoing
 Ciências da Saúde (Doutoramento)
Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal
"Targeted therapy in aggressive thyroid cancer - unravelling novel resistance mechanisms, predictive biomarkers and therapeutic targets" (THESIS/DISSERTATION)
2020/09/21 - 2022/02/22
Concluded
 Biologia Molecular e Genética (Mestrado)
Universidade de Lisboa Faculdade de Ciências, Portugal
"Study of molecular and cellular mechanisms involved in anaplastic thyroid carcinoma aggressiveness and response to therapy" (THESIS/DISSERTATION)
 19 out of 20
2016/09/16 - 2019/06/30
Concluded
 Biologia (Licenciatura)
Major in Biologia Molecular e Genética
Universidade de Lisboa Faculdade de Ciências, Portugal
"Ticks as vectors of pathogens with an interest in Public Health" (THESIS/DISSERTATION)
 17 out of 20
Projects

Grant

Designation Funders
2023/09/22 - Current Gold-nanoparticles in thyroid cancer cell lines
LISBOA2030-FEDER-00751700
Instituto Português de Oncologia de Coimbra Francisco Gentil EPE, Portugal

Universidade de Lisboa Faculdade de Farmácia, Portugal
2022/09/12 - Current Targeted therapy in aggressive thyroid cancer - unravelling novel resistance mechanisms, predictive biomarkers and therapeutic targets
UI/BD/154256/2022
PhD Student Fellow
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM)

Instituto Português de Oncologia de Lisboa Francisco Gentil EPE
Ongoing

Other

Designation Funders
2024/09/30 - Current Deflamin in thyroid cancer cells
A
PhD Student Fellow
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal

Universidade de Lisboa Instituto Superior de Agronomia, Portugal
2020/09/21 - 2022/02/22 Study of molecular and celular mechanisms involved in anaplastic thyroid carcinoma aggressiveness and response to therapy
1022-A
Master Student Fellow
Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
 Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM)

Merck SA

Instituto Português de Oncologia de Lisboa Francisco Gentil EPE
Ongoing
2018/09/16 - 2020/07/10 Ticks as vectors of pathogens with an interest in Public Health
Unknown
Research Fellow
2019/09/20 - 2019/12/10 Characterization of gravepine phytaspases in pathogen resistance
Unknown
Student
Outputs

Publications

Conference abstract
  1. Catarina Regala; Carlos Marques; Ana Saramago; Rodrigues, Ricardo; Branca Cavaco; Valeriano Leite; Tiago Nunes da Silva. "Lenvatinib in the treatment of anaplastic thyroid cancer: experience of a single center.". Paper presented in Congresso Português de Endocrinologia - 76ª Reunião Anual da SPEDM, Porto, 2025.
    Accepted
  2. Rodrigues, Ricardo; Carolina Pires; Carmo Martins; Valeriano Leite; Tiago Nunes da Silva; Branca Maria Cavaco. "LENVATINIB AND EGFR COMBINED INHIBITION DIFFERENTIALLY MODULATES TARGETS AND PATHWAYS IN RET/PTC, NRAS AND BRAF MUTATED THYROID CANCER CELLS". Paper presented in Congresso Português de Endocrinologia - 76ª Reunião Anual da SPEDM, 2025.
  3. Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Carmo Martins; Ana Sofia Carvalho; Hans C. Beck; Rune Matthiesen; Branca Maria Cavaco. "DEVELOPMENT OF A RET/PTC1 THYROID CANCER CELL VARIANT WITH LENVATINIB RESISTANCE – A TOOL TO INVESTIGATE DRUG RESPONSE AND NOVEL THERAPEUTIC APPROACHES". Paper presented in Congresso Português de Endocrinologia - 76ª Reunião Anual da SPEDM, 2025.
  4. Tiago Nunes da Silva; Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Miguel Rito; Saudade Andre; Raquel Dias; Valeriano Leite; Branca Maria Cavaco. "Liquid biopsy in the follow-up of a patient with BRAF positive anaplastic thyroid cancer and breast cancer". Paper presented in 46th Annual Meeting of the European Thyroid Association (ETA) 2024, Athens, 2024.
  5. Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Carmo Martins; Tiago Silva; Leite, Valeriano; Branca M. Cavaco. "Establishment and characterisation of a RET/PTC1 thyroid cancer-derived cell line (TPC-1) variant with resistance to lenvatinib.". Paper presented in 6th ASPIC International Congress, Faro, 2024.
  6. Rodrigues, Ricardo; Pires, Carolina; Carmo Martins; Valeriano Leite; Tiago Nunes da Silva; Branca Maria Cavaco. "TARGETING EGFR IN COMBINATION WITH LENVATINIB IN THYROID CANCER CELLS". Paper presented in 75ª Reunião Anual da SPEDM, 2024.
    Accepted
  7. Rodrigues, Ricardo; Tiago Nunes da Silva; Ana Saramago; Pires, Carolina; Miguel Rito; Saudade André; Raquel Dias; Valeriano Leite; Branca Maria Cavaco. "IS LIQUID BIOPSY A PROMISING TOOL FOR BRAF+ ANAPLASTIC THYROID CANCER MANAGEMENT? A CASE REPORT". Paper presented in Congresso Português de Endocrinologia – 75ª Reunião Anual da SPEDM, 2024.
    Accepted
  8. Rodrigues, Ricardo; Ana Teresa Pinto; Marta Pojo; Diana Pacheco Sousa; Rune Matthiesen; Ana Sofia Carvalho; Hans C. Beck; et al. "SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells.". Paper presented in NMS Research Week, Lisbon, 2023.
    Accepted
  9. Tiago Nunes da Silva; Catarina Regala; Rodrigues, Ricardo; João Roque; Inês Damásio; Branca M. Cavaco; Valeriano Leite. Corresponding author: Tiago Nunes da Silva. "Effectiveness of lenvatinib in progressive metastatic radioiodine refractory well differentiated and poorly differentiated thyroid carcinoma". Paper presented in 45th Annual Meeting of the European Thyroid Association (ETA) 2023, 2023.
  10. Catarina Regala; Tiago Nunes da Silva; Ricardo Rodrigues; Branca M. Cavaco; Valeriano Leite. Corresponding author: Catarina Regala. "24 HORAS PARA REESCREVER O DESFECHO DE UM CARCINOMA ANAPLÁSICO COM DABRAFENIB E TRAMETINIB". Paper presented in 74ª Reunião Anual da Sociedade Portuguesa de Endocrinologia Diabetes e Metabolismo, 2023.
  11. Ricardo Rodrigues; Ana Pinto; Marta Pojo; Diana Pacheco Sousa; Ana Sofia Carvalho; Hans C. Beck; Matthiesen, Rune; et al. "SPRY4 COMO POTENCIAL MEDIADOR DO PAPEL ANTI-TUMORAL DOS MACRÓFAGOS NO CARCINOMA ANAPLÁSICO DA TIRÓIDE". Paper presented in 74ª Reunião Anual da Sociedade Portuguesa de Endocrinologia Diabetes, Vilamoura, 2023.
    Published
  12. Tiago Nunes da Silva; Ricardo Rodrigues; Miguel Rito; Ana Saramago; Pires, Carolina; Mariana Horta; Valeriano Leite; Branca M. Cavaco. Corresponding author: Tiago Nunes da Silva. "A clinical and molecular study of a real-world cohort of BRAF V600E anaplastic thyroid carcinoma treated with Dabrafenib and Trametinib". Paper presented in 44th Annual Meeting of the European Thyroid Association, Brussels, 2022.
    Accepted
  13. Ricardo Rodrigues; Ana Pinto; Marta Pojo; Diana Pacheco Sousa; Ana Sofia Carvalho; Hans C. Beck; Rune Matthiesen; et al. Corresponding author: Ana Pinto. "The dual role of tumour-associated macrophages in anaplastic thyroid cancer". Paper presented in 5th ASPIC International Congress, Porto, 2022.
  14. Tiago Nunes da Silva; Ricardo Rodrigues; Miguel Rito; Ana Saramago; Pires, Carolina; Mariana Horta; Valeriano Leite; Branca M. Cavaco. Corresponding author: Tiago Nunes da Silva. "Estudo molecular de doentes com carcinoma anaplásico da tiróide tratados com Dabrafenib e Trametinib". Paper presented in 73ª reunião anual da Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo, Vilamoura, 2022.
  15. Joana Simões-Pereira; Ana Saramago; Ricardo Rodrigues; Marta Pojo; Pires, Carolina; Mariana Horta; Dolores López-Presa; et al. Corresponding author: Joana Simões-Pereira. "Factores preditivos da resposta/avidez ao iodo nos carcinomas papilares da tiróide metastáticos". Paper presented in 73ª reunião anual da Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo, Vilamoura, 2022.
  16. Ricardo Rodrigues; Miguel Rito; Mariana Horta; Ana Saramago; Pires, Carolina; Valeriano Leite; Tiago Nunes da Silva; Branca Maria Cavaco. "Molecular characterization of patients with BRAF V600E-positive anaplastic thyroid cancer under Dabrafenib and Trametinib treatment". Paper presented in II ASPIC-ASEICA INTERNATIONAL MEETING - CURRENT TRENDS IN PRECISION MEDICINE IN CANCER, 2021.
  17. Tiago Nunes da Silva; Mariana Horta; Miguel Rito; Ricardo Rodrigues; Branca M. Cavaco; Valeriano Leite. Corresponding author: Tiago Nunes da Silva. "Mudança de paradigma no tratamento do carcinoma anaplásico da tiroide com dabrafenib e trametinib: resultados de um estudo caso-controlo". Paper presented in 72ª reunião anual da Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo, 2021.
Conference poster
  1. Rodrigues, Ricardo; Pires, Carolina; Carmo Martins; Valeriano Leite; Tiago Nunes da Silva; Branca Maria Cavaco. "LENVATINIB AND EGFR COMBINED INHIBITION DIFFERENTIALLY MODULATES TARGETS AND PATHWAYS IN RET/PTC, NRAS AND BRAF MUTATED THYROID CANCER CELLS". Paper presented in Congresso Português de Endocrinologia - 76ª Reunião Anual da SPEDM, 2025.
  2. Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Carmo Martins; Ana Sofia Carvalho; Hans C. Beck; Rune Matthiesen; Branca Maria Cavaco. "DEVELOPMENT OF A RET/PTC1 THYROID CANCER CELL VARIANT WITH LENVATINIB RESISTANCE – A TOOL TO INVESTIGATE DRUG RESPONSE AND NOVEL THERAPEUTIC APPROACHES". Paper presented in Congresso Português de Endocrinologia - 76ª Reunião Anual da SPEDM, 2025.
  3. Tiago Nunes da Silva; Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Miguel Rito; Saudade André; Raquel Dias; Valeriano Leite; Branca Maria Cavaco. "Liquid biopsy in the follow-up of a patient with BRAF positive anaplastic thyroid cancer and breast cancer". Paper presented in 46th Annual Meeting of the European Thyroid Association (ETA) 2024, 2024.
  4. Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Carmo Martins; Tiago Silva; Leite, Valeriano; Branca M. Cavaco. "Establishment and characterisation of a RET/PTC1 thyroid cancer-derived cell line (TPC-1) variant with resistance to lenvatinib.". Paper presented in 6th ASPIC International Congress, 2024.
  5. Rodrigues, Ricardo; Ana Teresa Pinto; Marta Pojo; Matthiesen, Rune; Ana Sofia Carvalho; Hans C. Beck; Pires, Carolina; et al. "SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells". Paper presented in NMS Research Week, 2023.
  6. Rodrigues, Ricardo; Ana Pinto; Marta Pojo; Diana Pacheco Sousa; Ana Sofia Carvalho; Hans C. Beck; Rune Matthiesen; et al. Corresponding author: Ana Pinto. "The dual role of tumour-associated macrophages in anaplastic thyroid cancer". Paper presented in 5th ASPIC International Congress., 2022.
  7. Joana Simões Pereira; Ana Saramago; Ricardo Rodrigues; Pires, Carolina; Marta Pojo; Mariana Horta; Dolores López-Presa; et al. Corresponding author: Joana Simões Pereira. "Factores preditivos da resposta/avidez ao iodo nos carcinomas papilares da tiróide metastáticos.". Paper presented in 73ª reunião anual da Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo, 2022.
  8. Ricardo Rodrigues; Miguel Rito; Mariana Horta; Ana Saramago; Pires, Carolina; Valeriano Leite; Tiago Nunes da Silva; Branca M. Cavaco. Corresponding author: Ricardo Rodrigues. "Molecular characterization of patients with BRAF V600E-positive anaplastic thyroid cancer under Dabrafenib and Trametinib treatment". Paper presented in II ASPIC-ASEICA INTERNATIONAL MEETING - CURRENT TRENDS IN PRECISION MEDICINE IN CANCER, 2021.
Journal article
  1. Fernanda Rosa; Carla Silva; Rodrigues, Ricardo; Mariana Esteves-Vieira; Sara Rosa; Deodália Dias,; Francisco Pina-Martins. "Island hitchhikers: pathogen agents of Madeira and Azores ticks". Ticks and Tick-borne Diseases (2024): https://doi.org/10.1007/s00436-024-08278-y.
    Submitted
  2. Joana Simões-Pereira; Ana Saramago; Ricardo Rodrigues; Marta Pojo; Pires, Carolina; Mariana Horta; Dolores López-Presa; et al. Corresponding author: Joana Simões-Pereira. "Clinical and molecular characterisation of metastatic papillary thyroid cancer according to radioiodine therapy outcomes". Endocrine (2023):
    Accepted
  3. Ana Teresa Pinto; Marta Pojo; Rodrigues, Ricardo; Diana Pacheco Sousa; Rune Matthiesen; Ana Sofia Carvalho; Hans C. Beck; et al. Corresponding author: Ana Teresa Pinto. "SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells". Cancers 15 17 (2023): 4387. https://doi.org/10.3390/cancers15174387.
    Open access • Published • 10.3390/cancers15174387
  4. Dias, Daniela; Damásio, Inês; Marques, Pedro; Simões, Helder; Rodrigues, Ricardo; Cavaco, Branca Maria; Leite, Valeriano; et al. "Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin". European Thyroid Journal 12 3 (2023): http://dx.doi.org/10.1530/etj-22-0227.
    Accepted • 10.1530/etj-22-0227
  5. João Roque; Tiago Nunes Silva; Catarina Regala; Ricardo Rodrigues; Valeriano Leite. "Outcomes of lenvatinib therapy in poorly differentiated thyroid carcinoma". European Thyroid Journal (2023): https://doi.org/10.1530/ETJ-23-0003.
    10.1530/ETJ-23-0003
  6. Tiago Nunes da Silva; Rodrigues, Ricardo; Ana Saramago; Pires, Carolina; Miguel Rito; Mariana Horta; Carmo Martins; et al. Corresponding author: Tiago Nunes da Silva. "Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study". European Journal of Endocrinology 188 1 (2023): https://doi.org/10.1093/ejendo/lvac011.
    Published • 10.1093/ejendo/lvac011
Thesis / Dissertation
  1. "Study of molecular and cellular mechanisms involved in anaplastic thyroid carcinoma aggressiveness and response to therapy". Master, Fundação da Faculdade de Ciências da Universidade de Lisboa, 2022.
Activities

Oral presentation

Presentation title Event name
Host (Event location)
2025/02/02 LENVATINIB IN THE TREATMENT OF ANAPLASTIC THYROID CANCER: EXPERIENCE OF A SINGLE CENTER Congresso Português de Endocrinologia - 76ª Reunião Anual da SPEDM
(Porto, Portugal)
2024/02/02 TARGETING EGFR IN COMBINATION WITH LENVATINIB IN THYROID CANCER CELLS Congresso Português de Endocrinologia – 75ª Reunião Anual da SPEDM
Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (Portugal)
2024/02/02 IS LIQUID BIOPSY A PROMISING TOOL FOR BRAF+ ANAPLASTIC THYROID CANCER MANAGEMENT? A CASE REPORT Congresso Português de Endocrinologia – 75ª Reunião Anual da SPEDM
Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo
2023/10/12 SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells Cancro da Tiróide: Avanços no Diagnóstico e Terapêutica
Instituto Português de Oncologia de Lisboa Francisco Gentil (Lisboa, Portugal)
2023/10 SPRY4 as a Potential Mediator of the Anti-Tumoral Role of Macrophages in Anaplastic Thyroid Cancer Cells. Encontros de Investigação - Cancro da Tiroide: Avanços no diagnóstico e terapêutica
Instituto Português de Oncologia de Lisboa Francisco Gentil
2023/02/05 24 HORAS PARA REESCREVER O DESFECHO DE UM CARCINOMA ANAPLÁSICO COM DABRAFENIB E TRAMETINIB 74ª Reunião Anual da Sociedade Portuguesa de Endocrinologia Diabetes e Metabolismo
2023/02/04 SPRY4 COMO POTENCIAL MEDIADOR DO PAPEL ANTI-TUMORAL DOS MACRÓFAGOS NO CARCINOMA ANAPLÁSICO DA TIRÓIDE 74ª Reunião Anual da Sociedade Portuguesa de Endocrinologia Diabetes e Metabolismo
2022/10/27 The dual-role of tumour associated macrophages in anaplastic thyroid cancer. UIPM seminars
Instituto Português de Oncologia de Lisboa Francisco Gentil
2022/09/10 A clinical and molecular study of a real-world cohort of BRAF V600E anaplastic thyroid carcinoma treated with Dabrafenib and Trametinib 44th Annual Meeting of the European Thyroid Association
European Thyroid association (Brussels, Belgium)
2022/02/05 Estudo molecular de doentes com carcinoma anaplásico da tiroide tratados com dabrafenib e trametinib. 73ª reunião anual da Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo
(Portugal)
2021/01/22 Mudança de paradigma no tratamento do carcinoma anaplásico da tiroide com dabrafenib e trametinib: resultados de um estudo caso-controlo. 72ª reunião anual da Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo
(Portugal)
2020/05/20 Study of molecular and cellular mechanisms involved in anaplastic thyroid carcinoma aggressiveness and response to therapy UIPM seminars
Instituto Português de Oncologia de Lisboa Francisco Gentil

Event organisation

Event name
Type of event (Role) 		Institution / Organization
2023/05/20 - 2024/04/20 Mexer Contra o Cancro 1º Edição (2024/04/20)
Other (Member of the Organising Committee)
 Liga Portuguesa Contra o Cancro - Núcleo Regional do Sul, Portugal

Association member

Society Organization name Role
2024/09/12 - Current European Thyroid Association Junior Member
2021/12/21 - Current Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM)
2019/09/02 - Current Ordem dos Biólogos

Committee member

Activity description
Role 		Institution / Organization
2019/09/16 - 2022/02/22 Course president for the role of Course committee student representative from the Master's in Molecular Biology and Genetics
Coordinator
 Universidade de Lisboa Faculdade de Ciências, Portugal

Course / Discipline taught

Academic session Degree Subject (Type) Institution / Organization
2025/02/26 - Current Carcinogenesis – Underlying Molecular and Cellular Alterations, in the Masters in Biomedical Research - lecture about Clinical applicability of liquid biopsy in solid tumor monitoring and management Carcinogenesis – Underlying Molecular and Cellular Alterations (Mestrado) Universidade Nova de Lisboa Faculdade de Ciências Médicas, Portugal

Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
2019/03/06 - 2022/03/21 Aid in the experimental procedures in the laboratory classes of Forensic Biology of the Master of Human Biology and Environment at the Faculty of Sciences of the University of Lisbon. Forensic Biology (Mestrado) Universidade de Lisboa Faculdade de Ciências, Portugal

Mentoring / Tutoring

Topic Student name
2019/09/20 - 2020/07/20 Tutoria de Biologia Mónica Moisa
Distinctions

Award

2023 Honerable mention in Basic Investigation
Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), Portugal
2023 Bolsa "Projecto de Investigação SPEDM"
Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), Portugal
2023 Bolsa "Edward Limbert MERCK/SPEDM"
Sociedade Portuguesa de Endocrinologia, Diabetes e Metabolismo (SPEDM), Portugal
2022 PhD scholarship
iNOVA4Health, Portugal

Fundação para a Ciência e a Tecnologia, Portugal
2021 Honerable mention in Casuistic award
Sociedade Portuguesa de Endocrinologia Diabetes e Metabolismo, Portugal